Cytomedix Inc.

Cytomedix CEO Martin Rosendale Discusses Company in Interview with the Wall Street Transcript

● The Wall Street Transcript

Cytomedix Retains Dr. David F. Counts, Inventor of Company's Anti-Inflammatory Peptide Patent

Cytomedix CEO Issues Shareholder Update

Cytomedix Unveils Clinical Plans for the Development of Anti-Inflammatory Peptides

Cytomedix Announces Transition of Leadership Martin Rosendale Appointed CEO

Cytomedix Joins The Acute Long Term Hospital Association (ALTHA) as an Allied Member

Cytomedix Gains Access To U.S. Government Medical Facilities By Adding The AutoloGel™ System To The Federal Supply Schedule

Cytomedix Provides Update on Efforts to Secure Medicare Reimbursement for Its AutoloGel™ System

Cytomedix TO Exhibit at the 21ST Annaul Symposium On Advanced Wound Care (SAWC) April 24-27, 2008

Centers For Medicare And Medicaid Services (CMS) Reaches Final Coverage Decision on PRP GEL

Cytomedix Appoints Martin P. Rosendale Executive Vice President and Chief Operating Officer

The Kon-Lin Letter Initiates New Coverage of Cytomedix In Its February 2008 Issue With Initial Target of $4.50-$5.00 and Ultimate Target of $7-$9

Cytomedix Submits Comments in Response to CMS’ Proposed National Coverage Decision

Cytomedix Announces That CMS Preliminary Affirms Non-Coverage of PRP Gel

Cytomedix Files Registration Statement

Cytomedix To Restate Previously Issued Financial Statements For Stock-Option Related Compensation

Cytomedix Licenses Technology To Smith & Nephew

Cytomedix Issues Warrant Call

Cytomedix Submits Cost Effectiveness Study for AutoloGel™ to CMS

Cytomedix Announces Its Outside Patent Counsel Agrees to Take Equity Stake in the Company

Cytomedix Appoints David A. Hotchkiss as Vice President for Sales and Marketing

Cytomedix Autologel™ Clinical Trial Presentation Receives Top Award at APMA Annual Meeting

Cytomedix Announces Second Quarter 2006 Financial Results

CYTOMEDIX ISSUES WARRANT CALL
Potential $2.4 Million Cash Infusion

Cytomedix Joins New Russell Microcap Index

Cytomedix Announces Publication of the Autologel Diabetic Foot Ulcer Prospective Trial (Click here for a link to the article)

Cytomedix Licenses Patents To BIOMET For $2.6 Million

Cytomedix To Receive $2.2 Million From Existing Warrantholders

Cytomedix Announces Availability of Research Report on Company

Click here for our press release page.

AutoloGel System - for preperation of Platelet Rich Plasma Gel





	The Wall Street Transcript - August 18, 2008 Cytomedix Submits Response to CMS’s Proposed Decision Memorandum

[HOME] [ABOUT US] [AUTOLOGEL] [PATIENTS] [PROFESSIONALS] [INVESTORS] [CONTACT INFO] [WEB EMAIL]